With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line.
Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest.
In the 90s, MiniMed ran trials with a fully implantable system before Medtronic bought the company. Sayer admits the system with an implantable pump and sensor wasn’t particularly practical, but it planted the seeds for what could grow.
Now with Dexcom, the maker of the leading G6 continuous glucose monitoring (CGM) system — and the next-generation G7, which is expected to receive FDA clearance soon — Sayer has seen the integration of CGM with automated insulin delivery through partnerships with Insulet and Tandem Diabetes Care and he believes that, with pump penetration not yet passing 50% of intensive insulin users, room for growth remains.
“I’ve been around the fringes of this for a very long time,” Sayer told our sister site Drug Delivery Business News during the American Diabetes Association (ADA) Scientific Sessions this week. “I’ve often asked myself the question, ‘how big does this get?’ The feedback I’m hearing from users of both Tandem’s system and [Insulet’s] Omnipod 5 is incredibly positive.
“I think this is going to be a very important part of our business going forward.”
Get the full story at our sister site, Drug Delivery Business News.